Objective:

To assess the incidence of Clostridioides difficile infection (CDI) and other enteric infections in pediatric patients with inflammatory bowel disease (IBD) during exacerbations, and to identify possible predictors of CDI, which is crucial for tailored treatment strategies.

Key Findings:

• 32.6% of stool samples tested positive for infectious agents, indicating a significant prevalence.
• Clostridioides difficile and E. coli were the most frequently detected pathogens (11.8% each), highlighting the need for targeted diagnostics.
• Higher incidence of CDI in Crohn's disease patients compared to ulcerative colitis (17.2% vs. 8.5%), suggesting a need for tailored management strategies.
• Patients on biological treatments had a significantly higher risk of CDI (17.9% vs. 6.9%, P = 0.042), emphasizing the importance of monitoring in this group.
• One-third of hospitalized patients with exacerbation symptoms were confirmed to have CDI, underscoring the critical need for routine screening.

Interpretation:

The study highlights the significant prevalence of CDI and other enteric pathogens in pediatric IBD patients during exacerbations, emphasizing the need for systematic pathogen evaluation to guide treatment and improve patient outcomes.

Limitations:

• Retrospective design may introduce bias, potentially affecting the reliability of the findings.
• Limited generalizability due to the study being conducted in a single center, which may not reflect broader populations.
• Potential underreporting of infections due to reliance on stool cultures, which may miss some cases.

Conclusion:

The findings underscore the importance of evaluating for CDI and other pathogens in pediatric IBD patients during flare-ups, particularly in those with Crohn's disease and those receiving biological therapy, to inform clinical decision-making.